Altimmune

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Altimmune reports positive trial results and financial stability in Q4

Altimmune's Q4 2022 performance showcased positive trial results for pemvidutide, despite financial challenges from negligible revenue.
The company's strengths lie in promising drug outcomes, strong cash reserves, and differentiated trial approaches.
Challenges include revenue generation, financial pressures, regulatory discussions, and dosing decisions for NASH treatment.
Opportunities exist in attracting investors, showcasing broader drug impact, enhancing prescribing flexibility, and demonstrating drug efficacy.

Altimmune reports strong Q1 performance with promising NASH and obesity results

Altimmune's Q1 2023 performance showcased strong cash reserves, increased R&D investment, and promising results for pemvidutide in NASH and obesity.
The company's focus on Phase 3 readiness, potential partnerships, and innovative antiviral combinations positions it well for future growth and development.
Challenges with trial discontinuation rates and pending data from the Boingo trial require attention, but Altimmune's strengths and opportunities offer a positive outlook.

Altimmune reports promising Q2 results, eyes HepTcell program advancement

Altimmune's Q2 performance reflects financial stability and progress in clinical development.
Strengths lie in promising trial data, strong financial position, and strategic clinical approach.
Challenges include addressing trial effectiveness, clarifying criteria, and monitoring potential effects.
Opportunities exist in liver fat reduction, HepTcell development, and broad immune response selection.

Altimmune reports positive trial results and financial stability in Q3

Altimmune's Q3 2023 performance reflects strong financial position and ongoing research efforts.
Pemvidutide and HepTcell trials show promise in treating obesity, NASH, and HBV.
Analyst interest and positive trial results indicate growth potential for Altimmune.
Focus on innovation and collaboration key to navigating challenges and seizing opportunities.

Altimmune reports promising trial results and seeks strategic partnerships for growth

Altimmune's Q4 performance reflected significant R&D investment and positive trial outcomes.
Strengths lie in pemvidutide's efficacy on liver fat reduction, MRI analysis, and oral formulation progress.
Challenges include partnership agreements, financial losses, and Phase III trial initiation timing.
Opportunities exist in IND development, trial enrollment progress, and strategic partnerships for market growth.

Altimmune reports promising trial results and seeks strategic partnerships

Altimmune's Q1 2024 performance reflects increased R&D expenses leading to a net loss, but the company maintains a strong cash position for future endeavors.
Pemvidutide's promising results in obesity trials position it as a potential best-in-class therapy, while ongoing studies aim to differentiate its use in treating liver conditions.
Despite challenges in partnership and regulatory discussions, Altimmune's compound shows strengths in tolerability and potential for expansion into new indications.

Altimmune reports strong Q3 performance, poised for growth opportunities

Altimmune's Q3 performance reflects financial strength and progress in key trials, positioning the company for future success.
While challenges such as FDA alignment and funding exist, strategic partnerships and additional indications present growth opportunities.
Investor interest remains high, supported by positive trial results and management's strategic focus on advancing the pipeline.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Altimmune (ALT) news for Monday includes positive news about a vaccine to treat the coronavirus from China have ALT stock soaring higher.
The post Altimmune News: ALT Stock Rockets 110% on Coronavirus Vaccine News appeared first on InvestorPlace.

Altimmune News: ALT Stock Rockets 110% on Coronavirus Vaccine News

Clorox

Gilead Sciences

Inovio Pharmaceuticals

Lakeland Industries

NanoViricides

Novavax

Zoom Video

The coronavirus fear is now a pandemic, at least in the markets. All major American averages were down over 3% on Friday, after what has been the worst week since the financial crisis more than a decade ago.

The Top Stocks to Beat the Coronavirus Market Scare

Altimmune: On The Sidelines For Wuhan Coronavirus Crisis

Preclinical study shows systemic activity of ALT-702 following local administration

Altimmune Announces Positive Results for ALT-702 in Preclinical Model of Colorectal Cancer

Altimmune: Determining If Pipeline Programs Are Distractions Or Directions

Altimmune's (ALT) CEO Vipin Garg on Q3 2019 Results - Earnings Call Transcript

GAITHERSBURG, Md., Oct.  10, 2019  (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that management will participate in the following investor conferences during the months of October and November:

Altimmune to Participate in Upcoming Investor Conferences

GAITHERSBURG, Md., Sept.  09, 2019  (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced it has appointed M. Scott Harris, M.D. as Chief Medical Officer. Dr. Harris is succeeding Dr. Sybil Tasker, who resigned June 30, 2019 to continue her professional focus on infectious diseases.

Altimmune Appoints M. Scott Harris, M.D.

Phase 1b clinical trial will study effect of dosing methodology on immune response to intranasal anthrax vaccine Phase 1b clinical trial will study effect of dosing methodology on immune response to intranasal anthrax vaccine

Altimmune Announces $3.7 Million in Additional BARDA Funding to Advance NasoShield™ Clinical Development

Altimmune, Inc. (ALT) CEO Vipin Garg on Q2 2019 Results - Earnings Call Transcript

Clinical stage immunotherapeutic biotechnology company Altimmune Inc (NYSE: ALT) today had a large opening gap of 12.28%.

What Caused The Opening Gap In Altimmune?

Altimmune shares are trading higher after the company announced it will acquire Spitfire Pharma, which will add a non-alcoholic steatohepatitis (NASH) drug candidate to the company's portfolio.

Altimmune To Acquire Spitfire Pharma For $5M, Add NASH Drug To Portfolio

Shares of Altimmune Inc. soared 14% in premarket trading Tuesday, after the biopharmaceutical company announced a deal to buy Spitfire Pharma Inc., which is developing a treatment for non-alcoholic steatohepatitis, known as NASH.

Altimmune's stock soars after adding NASH candidate with purchase of Spitfire Pharma

Altimmune has a short list of pending catalysts that are capable of transforming the company and the stock. However, the company has yet to close a deal.

Altimmune: I Look For A Pulse While The Company Looks For A Partner

Altimmune, Inc. (ALT) CEO Vipin Garg on Q1 2019 Results - Earnings Call Transcript

Altimmune recently presented their HepTcell phase I results at the International Liver Congress in Vienna, Austria that provided some suggestions for designing the phase II study.

Altimmune Plans To Progress HepTcell But Market Shrugs It Off

Altimmune, Inc. (ALT) CEO Vipin Garg on Q4 2018 Results - Earnings Call Transcript

Altimmune Inc, which develops immunotherapies and vaccines, is seeing its stock surge on 15 times its average volume after the company reported the results of a midstage study of its lead candidate NasoVAX.

Altimmune's Flu Shot Study: What You Need To Know

Positive results from a midstage influenza study sent Altimmune Inc. shares sharply higher on Tuesday.

What’s Next for Altimmune’s Influenza Vaccine

Shares of Altimmune Inc. soared 36% in active premarket trade Tuesday.

News for Altimmune Stock (ALT)